Suven Life Sciences Limited - Asset Resilience Ratio

Latest as of September 2025: 74.12%

Suven Life Sciences Limited (SUVEN) has an Asset Resilience Ratio of 74.12% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SUVEN working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Rs2.50 Billion
≈ $27.04 Million USD Cash + Short-term Investments

Total Assets

Rs3.37 Billion
≈ $36.49 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2012–2025)

This chart shows how Suven Life Sciences Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Suven Life Sciences Limited.

Liquid Assets Composition Over Time

This chart breaks down Suven Life Sciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Suven Life Sciences Limited (SUVEN) long-term investment share to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs11.77 Million 0.35%
Short-term Investments Rs2.49 Billion 73.77%
Total Liquid Assets Rs2.50 Billion 74.12%

Asset Resilience Insights

  • Very High Liquidity: Suven Life Sciences Limited maintains exceptional liquid asset reserves at 74.12% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Suven Life Sciences Limited Industry Peers by Asset Resilience Ratio

Compare Suven Life Sciences Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Yunnan Baiyao Group Co Ltd
SHE:000538
Drug Manufacturers - Specialty & Generic 8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Harbin Gloria Pharmaceuticals
SHE:002437
Drug Manufacturers - Specialty & Generic 9.04%
Jiuzhitang Co Ltd
SHE:000989
Drug Manufacturers - Specialty & Generic 7.86%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%

Annual Asset Resilience Ratio for Suven Life Sciences Limited (2012–2025)

The table below shows the annual Asset Resilience Ratio data for Suven Life Sciences Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 33.27% Rs449.79 Million
≈ $4.86 Million
Rs1.35 Billion
≈ $14.62 Million
+6.62pp
2024-03-31 26.65% Rs759.35 Million
≈ $8.21 Million
Rs2.85 Billion
≈ $30.81 Million
-62.22pp
2023-03-31 88.87% Rs3.46 Billion
≈ $37.38 Million
Rs3.89 Billion
≈ $42.06 Million
+47.07pp
2022-03-31 41.80% Rs451.62 Million
≈ $4.88 Million
Rs1.08 Billion
≈ $11.68 Million
-15.76pp
2021-03-31 57.57% Rs739.26 Million
≈ $7.99 Million
Rs1.28 Billion
≈ $13.89 Million
+57.54pp
2020-03-31 0.03% Rs494.00K
≈ $5.34K
Rs1.82 Billion
≈ $19.68 Million
-22.29pp
2019-03-31 22.32% Rs2.32 Billion
≈ $25.08 Million
Rs10.39 Billion
≈ $112.35 Million
-9.43pp
2018-03-31 31.74% Rs2.90 Billion
≈ $31.36 Million
Rs9.14 Billion
≈ $98.79 Million
-5.20pp
2017-03-31 36.95% Rs3.01 Billion
≈ $32.59 Million
Rs8.16 Billion
≈ $88.22 Million
+36.94pp
2016-03-31 0.00% Rs364.00K
≈ $3.94K
Rs7.86 Billion
≈ $84.96 Million
0.00pp
2015-03-31 0.00% Rs364.00K
≈ $3.94K
Rs7.73 Billion
≈ $83.61 Million
0.00pp
2014-03-31 0.01% Rs364.00K
≈ $3.94K
Rs4.87 Billion
≈ $52.63 Million
-0.01pp
2013-03-31 0.02% Rs712.00K
≈ $7.70K
Rs3.34 Billion
≈ $36.13 Million
-1.55pp
2012-03-31 1.57% Rs44.73 Million
≈ $483.77K
Rs2.85 Billion
≈ $30.82 Million
--
pp = percentage points

About Suven Life Sciences Limited

NSE:SUVEN India Drug Manufacturers - Specialty & Generic
Market Cap
$974.11 Million
Rs90.07 Billion INR
Market Cap Rank
#9082 Global
#445 in India
Share Price
Rs341.55
Change (1 day)
-2.37%
52-Week Range
Rs126.65 - Rs392.05
All Time High
Rs392.05
About

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candida… Read more